Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00679601 · ClinicalTrials.gov registry record · Phase 2

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)

A Phase 2 study of Onychomycosis, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT00679601 is a Phase 2 study of Onychomycosis that has completed, run by Pfizer. The registered enrollment target is 20 participants, below the 93-participant average among 11 other Onychomycosis trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00679601, a Phase 2 study of Onychomycosis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.

Conditions Studied

Interventions

  • DRUG AN2690

Study Locations (1)

Texas

  • J&S Studies - Bryan

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2007-03-31
Est. Completion 2007-05-31
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00679601

The ClinicalTrials.gov registry entry for NCT00679601 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 93-participant average among 11 other Onychomycosis trials with a reported enrollment target (78% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Onychomycosis appearing as the primary indexed condition, and to 1 intervention - of which AN2690 is the first listed.

NCT00679601 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00679601 about?

NCT00679601 is a clinical study titled "Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)". The purpose of the study is to determine the absorption and systemic pharmacokinetics of AN2690 following daily application to all ten (10) toenails for 28 days.

What is the current status of trial NCT00679601?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-03-31. Estimated completion is 2007-05-31.

What conditions does trial NCT00679601 study?

This clinical trial studies the following conditions: Onychomycosis.

What interventions are being tested in trial NCT00679601?

The interventions under investigation include: AN2690 (DRUG).

Who is sponsoring clinical trial NCT00679601?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00679601 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Onychomycosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.